NOVELION THERAPEUTICS INC.
NOVELION THERAPEUTICS INC. (NVLN): 2 pipeline candidates · ~6 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
6.2 months
D/E -3.88 · 0% dilution
Lead: Approved
2 candidates
N/A
N/A
A transparent, data-derived signal for NOVELION THERAPEUTICS INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$51.9M
Quarterly Burn
$33.0M
Runway
6.2 mo
Revenue
$32.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in NOVELION THERAPEUTICS INC.'s pipeline?
NOVELION THERAPEUTICS INC. (NVLN) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is NOVELION THERAPEUTICS INC.'s lead drug candidate?
NOVELION THERAPEUTICS INC.'s most advanced tracked candidate is juxtapid (Approved).
What is NOVELION THERAPEUTICS INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NOVELION THERAPEUTICS INC. has approximately 6.2 months of cash runway.
Who is the CEO of NOVELION THERAPEUTICS INC.?
Ben Harshbarger Interim is the chief executive officer of NOVELION THERAPEUTICS INC. (NVLN).
Get the full picture on NOVELION THERAPEUTICS INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.